Von Hippel-Lindau-Czermak Syndrome – Overview & Treatment
Von Hippel-Lindau-Czermak syndrome is a rare hereditary condition that causes tumors and cysts to develop in multiple organs, primarily affecting the brain, spinal cord, eyes, and kidneys.
Wissenswertes über "Von Hippel-Lindau-Czermak Syndrome"
Von Hippel-Lindau-Czermak syndrome is a rare hereditary condition that causes tumors and cysts to develop in multiple organs, primarily affecting the brain, spinal cord, eyes, and kidneys.
What is Von Hippel-Lindau-Czermak Syndrome?
Von Hippel-Lindau-Czermak syndrome (VHL syndrome) is a rare, inherited disorder belonging to the group of hereditary tumor syndromes. It is caused by a mutation in the VHL tumor suppressor gene located on chromosome 3 and follows an autosomal dominant inheritance pattern. This means that a mutation in just one copy of the gene is sufficient to cause the disease. The syndrome is named after physicians Eugen von Hippel, Arvid Lindau, and Johann Nepomuk Czermak, who each made significant contributions to its clinical description.
VHL syndrome leads to the uncontrolled growth of both benign and malignant tumors as well as cysts in various organs. A hallmark feature is the development of hemangioblastomas -- highly vascularized tumors -- in the central nervous system and the retina of the eye.
Causes and Genetics
The underlying cause is a germline mutation in the VHL gene. Under normal circumstances, this gene encodes a protein that regulates cell growth and controls the formation of new blood vessels (angiogenesis). When this function is lost, uncontrolled cell proliferation and excessive vascularization occur.
- Inheritance: autosomal dominant (an affected parent has a 50% chance of passing the mutation to each child)
- De novo mutations (without affected parents) are possible but less common
- Prevalence: approximately 1 in 36,000 individuals is affected
Symptoms
The symptoms of VHL syndrome vary widely depending on which organs are involved. The disease typically manifests in early adulthood but can also present during childhood.
Central Nervous System
- Hemangioblastomas of the cerebellum, brainstem, or spinal cord: headaches, balance disorders, coordination problems, weakness or paralysis
Eyes
- Retinal hemangioblastomas (formerly: angiomatosis retinae): visual disturbances up to and including blindness; often the first symptom in young adults
Kidneys
- Clear cell renal cell carcinoma and renal cysts: frequently bilateral, with an elevated risk of metastasis
Adrenal Glands
- Pheochromocytomas: hypertensive crises, palpitations, sweating, headaches
Pancreas
- Pancreatic cysts and neuroendocrine tumors: abdominal pain, digestive disturbances, and in advanced stages, diabetes mellitus
Inner Ear
- Endolymphatic sac tumors: hearing loss, tinnitus, dizziness
Diagnosis
Diagnosis of VHL syndrome is established through clinical evaluation and molecular genetic testing. Key investigations include:
- Genetic testing: Detection of the VHL gene mutation via blood test (gold standard)
- MRI of the brain and spinal cord: Screening for hemangioblastomas
- Ophthalmoscopy (fundoscopy): Assessment of the retina for vascular lesions
- Abdominal ultrasound, CT, or MRI: Evaluation of the kidneys, adrenal glands, and pancreas
- Laboratory tests: Urinary or plasma catecholamines and metanephrines (to rule out pheochromocytoma)
In individuals with a known family history, regular surveillance screenings are recommended starting in childhood.
Treatment
There is currently no curative treatment for the underlying genetic mutation. Therapy focuses on preventing complications and treating tumors at an early stage.
Surgical Treatment
- Surgical removal of CNS hemangioblastomas when symptomatic or showing progressive growth
- Partial nephrectomy or nephrectomy for renal cell carcinoma
- Resection of adrenal pheochromocytomas
Ophthalmic Treatment
- Laser photocoagulation or cryotherapy of retinal hemangioblastomas to prevent vision loss
Medical Therapy
- Belzutifan (HIF-2alpha inhibitor): approved by the FDA in 2021 and by the EMA in 2023 for treatment of VHL-associated tumors not requiring immediate surgery
- VEGF inhibitors and mTOR inhibitors for specific tumor manifestations
Ongoing Surveillance
Due to multi-organ involvement, lifelong interdisciplinary follow-up care is essential. Regular monitoring by neurologists, ophthalmologists, urologists, endocrinologists, and clinical geneticists is strongly recommended.
Prognosis
The prognosis of VHL syndrome depends greatly on the timing of diagnosis and the consistency of follow-up care. Early detection through regular screening can significantly improve quality of life and prevent life-threatening complications. Renal cell carcinoma is the most common cause of death in affected individuals if not treated in a timely manner.
References
- Lonser RR et al. - von Hippel-Lindau disease. Lancet. 2003;361(9374):2059-2067.
- Maher ER et al. - Von Hippel-Lindau disease: a clinical and scientific review. European Journal of Human Genetics. 2011;19(6):617-623.
- National Institutes of Health (NIH) - Von Hippel-Lindau Disease Information Page. https://www.ninds.nih.gov (accessed 2024)
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryDementia praecox
Phosphatidic Acid
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Von Hippel-Lindau-Czermak Syndrome + Von Hippel-Lindau Syndrome + VHL Syndrome + Hippel-Lindau Syndrome